Dragonstone Capital
龙磐资本
Dragonstone Capital (龙磐投资) is a Chinese venture capital firm active in healthcare and biotech investing. Per 5Y Capital's reporting, it led a $30 million Series A in ReviR Therapeutics in July 2024 , and has co-led or followed in other life-science deals including Shenyun Medical's RMB 100 million-plus round in early 2025 and AllinkBio's nearly $50 million Series A extension late that year . The fund appears to operate across early and growth stages in the sector, though elsewhere's corpus does not cover its founding, team, or full strategy in depth.
AI-generated — may contain errors, please verify.
Coverage
AllinkBio Closes Nearly $50 Million Series A Extension, BlueRun Ventures Continues to Double Down | BlueRun Family
Accelerating Clinical Development at Full Speed
Zean completes $40 million Series A+ round to accelerate development of myeloid cell engager pipeline | BlueRun Ventures Family
Focusing on unmet clinical needs in major disease areas such as cancer and autoimmune diseases.
Heyuan Medical Closes Funding Round Exceeding RMB 100 Million, Dalton Venture Co-Leads Investment, Multiple Breakthrough Technologies Empower Heart Failure Management | Dalton Venture News
Recently, **Shanghai-based United InnoMed® announced the completion of a new funding round exceeding 100 million RMB**. The round was **jointly led by Dalton Venture and Dragonstone Capital**, with follow-on investments from Yinglian Health Fund and Tianrui Fengnian Capital. Existing investor Lilly Asia Ventures continued to increase its stake. **The proceeds will be primarily used for the R&D and registration clinical trials of multiple core pipeline products.**
If wisdom lacks the courage of execution, it is all in vain | 5Y News Monthly
The big news from last month.
This AI drug discovery company just raised 200 million yuan in its Series A. What's it planning to do?
AI-powered drug discovery has a bright future ahead.
5Y News | 5Y Capital Portfolio Company ReviR Therapeutics Raises $30 Million in Series A Funding
Continuing to advance "oral gene therapy" through AI+RNA.
Breaking Into Silicon Valley, David Wei Blazes a New Trail for Dollar Funds | Getting in the Game
"There's no way to stop the exchange of ideas between people."
A group of people everyone wants to know
They're scattered, hidden, yet everywhere all at once.
The Most Under-the-Radar Healthcare Fund: 13 Years, 10 Billion RMB, DPI Over 3 | RuJu
Technological upheaval, capital reallocation, and the tangled roots of an era have together forged this intricate commercial world. Between innovation and capital, as once-reliable operating models face new challenges and inherited industry norms—long carried west to east—come undone, people urgently seek a new map and a new order.
From Angel to G+ Round: 5 Early-Stage FreeS Fund Portfolio Companies Raise Over 3 Billion RMB | FreeS Family Funding News · Vol 14
Looking forward to working alongside more outstanding founders.
